Investigational Site Number 056003

Leuven 3000

0 studies enrolling now · 3 studies all time

What they study most

Acute Coronary Syndrome, Hematopoietic Neoplasm, Pompe Disease

Studies at this site

• Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib — Stopped early
• Alglucosidase Alfa Pompe Safety Sub-Registry — Completed
• Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) — Completed